Invasive fungal infection following chemotherapy for acute myeloid leukaemia—Experience from a developing country

The incidence of invasive fungal infections (IFI) is believed to be higher in patients with acute myeloid leukaemia (AML) undergoing chemotherapy in non‐HEPA‐filtered rooms. The aim of this study is to review the incidence of IFI in a large cohort of patients with AML treated at a single centre in India. Two hundred and twenty‐two patients with AML treated with either induction chemotherapy or salvage chemotherapy between 2008 and 2013 were studied retrospectively. IFI was defined as per the revised EORTC‐MSG criteria. Data on type of chemotherapy, prophylactic strategies, engraftment (ANC>500), the presence of IFI and survival were collected. IFI was diagnosed in 86 patients (38.7%) with proven IFI in 12 (5.4%). Use of posaconazole prophylaxis (P=.001) was the only factor associated with reduced incidence of IFI. Survival in patients with proven IFI was lower than those without proven IFI, but not statistically significant (59.4% vs 78.5%; P=.139). There is a high incidence of IFI during induction chemotherapy for acute myeloid leukaemia in developing countries. Posaconazole prophylaxis was associated with a significantly lower incidence of IFI. Optimal yet cost‐effective strategies for prevention and early diagnosis of IFI are required to improve survival in patients undergoing chemotherapy for AML.

[1]  H. Rohde,et al.  Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. , 2017, International journal of antimicrobial agents.

[2]  B. George,et al.  Acute myeloid leukaemia: challenges and real world data from India , 2015, British journal of haematology.

[3]  S. Marcella,et al.  An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States , 2015, Journal of medical economics.

[4]  A. Guarascio,et al.  Review of the New Delayed‐Release Oral Tablet and Intravenous Dosage Forms of Posaconazole , 2015, Pharmacotherapy.

[5]  V. Pavone,et al.  Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) , 2015, Haematologica.

[6]  R. Foà,et al.  Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. , 2014, Leukemia research.

[7]  J. Perfect,et al.  Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study , 2014, Cancer medicine.

[8]  N. Winick,et al.  Association of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemia , 2014, Pediatric blood & cancer.

[9]  A. Chakrabarti,et al.  Empirical Amphotericin B therapy on Day 4 or Day 8 of Febrile Neutropenia , 2014, Mycoses.

[10]  D. Kontoyiannis,et al.  Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Patients in a Tertiary Cancer Center, 2009 to 2011 , 2013, Antimicrobial Agents and Chemotherapy.

[11]  M. Nucci,et al.  Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  John W. Wilson,et al.  The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole , 2013, American journal of hematology.

[13]  Amanda Blackford,et al.  Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. , 2013, Diagnostic microbiology and infectious disease.

[14]  I. Raad,et al.  Hospital environment and invasive aspergillosis in patients with hematologic malignancy. , 2012, American journal of infection control.

[15]  R. Foà,et al.  Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience , 2012, Haematologica.

[16]  Tim Spelman,et al.  Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period , 2012, Haematologica.

[17]  S. Kabra,et al.  Oral Voriconazole Versus Intravenous Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction: A Prospective, Randomized, Clinical Study , 2011, Journal of pediatric hematology/oncology.

[18]  P. Vanhems,et al.  Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[19]  K. Sepkowitz,et al.  IDSA GUIDELINES Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America , 2022 .

[20]  Mansher Singh,et al.  Infections in acute myeloid leukemia: an analysis of 382 febrile episodes , 2010, Medical oncology.

[21]  D. DeAngelo,et al.  Invasive fungal disease in patients treated for newly diagnosed acute leukemia , 2010, American journal of hematology.

[22]  M. Hallek,et al.  Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. , 2010, The Journal of antimicrobial chemotherapy.

[23]  A. Glasmacher,et al.  Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 , 2010, The Journal of antimicrobial chemotherapy.

[24]  A. Vekhoff,et al.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  H. Einsele,et al.  Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2008, International journal of hematology.

[26]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  B. Thiers.  Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .

[28]  W. Boersma,et al.  Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. , 2007, Respiratory medicine.

[29]  Theresa Hahn,et al.  Efficacy of High-Efficiency Particulate Air Filtration in Preventing Aspergillosis in Immunocompromised Patients With Hematologic Malignancies , 2002, Infection Control & Hospital Epidemiology.

[30]  M. Cheang,et al.  Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.